Bexarotene

In the US, Bexarotene (bexarotene systemic) is a member of the drug class miscellaneous antineoplastics and is used to treat Cutaneous T-cell Lymphoma.

US matches:

• Bexarotene


• Bexarotene Gel


• Bexarotene topical

Scheme

Rec.INN

ATC (Anatomical Therapeutic Chemical Classification)

L01XX25

CAS registry number (Chemical Abstracts Service)

0153559-49-0

Chemical Formula

C24-H28-O2

Molecular Weight

348

Therapeutic Category

Antineoplastic agent

Chemical Names

4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid (USAN)

p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid (WHO)

Foreign Names

• Bexarotenum (Latin)
• Bexaroten (German)
• Bexarotène (French)
• Bexaroteno (Spanish)

Generic Names

• Bexarotene (OS: BAN, USAN)
• Bexarotène (OS: DCF)
• LG 100069 (IS)
• LGD 1069 (IS)
• Targretyn (IS: Ligand)
• Targrexin (IS: Ligand)

Brand Names

• Targretin
  Alfa Wassermann, Italy; Andromaco, Chile; Cephalon, Belgium; Cephalon, Germany; Cephalon, Finland; Cephalon, France; Cephalon, United Kingdom; Cephalon, Ireland; Cephalon, Sweden; Eisai, Austria; Eisai, Hungary; Eisai, United States; Eisai Ltd, Luxembourg; Ferrer, Spain; Ligand, Czech Republic; Ligand, Netherlands; Ligand, Norway; Eisai Ltd.GB, Denmark

International Drug Name Search

Glossary

BAN	British Approved Name
DCF	Dénomination Commune Française
IS	Inofficial Synonym
OS	Official Synonym
Rec.INN	Recommended International Nonproprietary Name (World Health Organization)
USAN	United States Adopted Name
WHO	World Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.